EUVIMEDEUVIMED entdecken
Übersichtsarbeit

B cells in metabolic dysfunction-associated steatotic liver disease (MASLD): From mechanisms to therapeutic exploration

Leyao Jia, Xue Bai, Wenjing Ni, Shengxia Yin, Junping Shi, Yongfeng Yang, Jie Li

International Immunopharmacology · 2025-12 · 166 · 115553

DOI: 10.1016/j.intimp.2025.115553 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2025-12. Verfasst von Leyao Jia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing 210008, Jiangsu, China. Hauptthemen laut MEDLINE: B-Lymphocytes, Fatty Liver. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangsu Province, Nanjing Drum Tower Hospital, Nanjing University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 30 % of the global population and has become a major cause of chronic liver disease, encompassing progressive conditions like metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and related hepatocellular carcinoma (HCC). Adaptive immunity, particularly B cells, plays a critical role in MASLD pathogenesis. Different B cell subsets, including B1, B2 cells, and regulatory B cells (Bregs), participate in disease progression through various mechanisms, such as cytokine secretion, antibody production, and crosstalk between adipose tissue and the liver, influencing inflammation, insulin resistance, and fibrosis development. Key factors like B cell-activating factor (BAFF) and signaling pathways including toll-like receptor (TLR) signaling are involved in B cell activation and their pathogenic effects. Emerging therapeutic strategies target B cell migration or signaling pathways. This review summarizes current evidence on B cells' multifaceted roles in MASLD progression, focusing on their activation mechanisms in MASH-related fibrosis and exploring potential B cell-targeted therapeutic prospects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B-LymphocytesFatty LiverHumansAnimalsSignal TransductionLiverLiver Cirrhosis

Stichwörter der Autor:innen

B cellsMechanismMetabolic dysfunction-associated steatohepatitisMetabolic dysfunction-associated steatotic liver disease

Autor:innen und Institutionen

  • Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing 210008, Jiangsu, China.
  • Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, Jiangsu, China.
  • Department of Hepatology, The Affiliated Hospital & Institute of Hepatology and Metabolic Disease, Hangzhou Normal University, Hangzhou 310015, Zhejiang, China.
  • Department of infectious disease and liver disease, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing 210003, Jiangsu, China. Electronic address: yangyongfeng@njucm.edu.cn.
  • Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing 210008, Jiangsu, China; Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated H…

Förderung

  • Natural Science Foundation of Jiangsu Province
  • Nanjing Drum Tower Hospital
  • Nanjing University
  • National Natural Science Foundation of China

Zitieren

APA

Jia, L., Bai, X., Ni, W., Yin, S., Shi, J., Yang, Y., & Li, J. (2025). B cells in metabolic dysfunction-associated steatotic liver disease (MASLD): From mechanisms to therapeutic exploration. International Immunopharmacology, 166, 115553. https://doi.org/10.1016/j.intimp.2025.115553

Vancouver

Jia L, Bai X, Ni W, Yin S, Shi J, Yang Y, et al. B cells in metabolic dysfunction-associated steatotic liver disease (MASLD): From mechanisms to therapeutic exploration. International Immunopharmacology. 2025;166:115553. doi:10.1016/j.intimp.2025.115553

BibTeX
@article{Jia2025,
  author = {Jia, Leyao and Bai, Xue and Ni, Wenjing and Yin, Shengxia and Shi, Junping and Yang, Yongfeng and Li, Jie},
  title = {B cells in metabolic dysfunction-associated steatotic liver disease (MASLD): From mechanisms to therapeutic exploration},
  journal = {International Immunopharmacology},
  year = {2025},
  volume = {166},
  pages = {115553},
  doi = {10.1016/j.intimp.2025.115553}
}
Kostenlos starten →